Novel PDE6δ inhibitors for the treatment of K-Ras mutant pancreatic cancer
Medicine
Ref.-No.: 0803-5326-IKF
Technology
Researchers at the Max Planck Institute for Molecular Physiology have developed a novel class of inhibitors targeting PDE6δ, an enzyme critical for maintaining the dynamic distribution of K-Ras within cells.
These inhibitors are characterized by a benzene disulfonamide structure, which enables them to achieve powerful inhibition of the binding between PDE6δ and Ras. They present high affinity for PDE6δ, with a KD in the low nanomolar range.
Furthermore, in vitro experiments have provided compelling evidence of their efficacy, as these inhibitors significantly reduced proliferation of several pancreatic cancer cell lines.
Patent Information
International Patent Application No. PCT/EP2018/050699, filed on July 19, 2018.
Opportunity
We are open to research partnerships and license agreements to accelerate the integration of our PDE6δ inhibitors into the clinical practice.
PDF Download
- Ref.-No.: 0803-5326-IKF (228.0 KiB)
Contact
Dr. Ingrid Kapser-Fischer
Nutritionist, M.Sc.
Phone: +49 89 / 29 09 19-19
Email:
kapser-fischer@max-planck-innovation.de